{"ModuleTitle": "Company Description", "CompanyName": "Repligen Corporation", "Symbol": "RGEN", "Address": "41 SEYON STREET BUILDING 1, SUITE 100, WALTHAM, Massachusetts, 02453, United States of America", "Phone": "7814499560", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "The following discussion of our business contains forward-looking statements\r\nthat involve risks and uncertainties. When used in this report, the words\r\n\"intend,\" \"anticipate,\" \"believe,\" \"estimate,\" \"plan\" and \"expect\" and similar\r\nexpressions as they relate to us are included to identify forward-looking\r\nstatements. Our actual results could differ materially from those anticipated in\r\nthese forward-looking statements and are a result of certain factors, including\r\nthose set forth under \"Risk Factors\" and elsewhere in this Annual Report on Form\r\n 10-K\r\n(\"Form\r\n10-K\").\r\nReferences throughout this Form\r\n10-K\r\nto \"Repligen Corporation\", \"Repligen\", \"we\", \"us\", \"our\", or the \"Company\" refer\r\nto Repligen Corporation and its subsidiaries, taken as a whole, unless the\r\ncontext otherwise indicates.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f26%2f0001193125-20-050136.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Jon K. Snodgres", "title": "Secretary, Chief Financial & Accounting Officer"}, {"name": "Ralf Kuriyel", "title": "Senior Vice President-Research & Development"}, {"name": "Steve Curran", "title": "Vice President-Global Operations"}, {"name": "Tony J. Hunt", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}